ID

21066

Description

An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01902862

Lien

https://clinicaltrials.gov/show/NCT01902862

Mots-clés

Versions (1)
  1. 07/04/2017 07/04/2017 -
Téléchargé le

7 avril 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

  • Plus récent
  • Plus ancien
  • Favori
  • Plus récent
    • Plus récent
    • Plus ancien
    • Favori

Aucun commentaire

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Lymphoma, Follicular NCT01902862

Anglais

Eligibility Lymphoma, Follicular NCT01902862

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
participants with histologically confirmed relapsed or refractory follicular stage iii or iv, grade 1 and 2, cluster of differentiation 20 plus (cd20+) lymphoma (who-world health organization) that requires therapy
Description

Lymphoma, Follicular; histological diagnosis; Recurrent disease; Refractory Disease | Lymphoma stage | Cell positive for CD20 antigen

Type de données

boolean

Alias
UMLS CUI [1,1]
C0024301
UMLS CUI [1,2]
C0679557
UMLS CUI [1,3]
C0277556
UMLS CUI [1,4]
C1514815
UMLS CUI [2]
C1272836
UMLS CUI [3]
C0882818
participants in whom treatment with rituximab is planned after greater than or equal to 2 cytostatic (inhibition of cell growth) previous therapies
Description

rituximab planned, prior chemotherapy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0393022
UMLS CUI [1,2]
C1301732
UMLS CUI [2]
C1514457
women must be either postmenopausal or sterilized; negative pregnancy test at screening
Description

postmenopausal state, sterilized, pregnancy

Type de données

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0015787
UMLS CUI [3]
C0032961
participants with total bilirubin below 1.5-fold upper limit of normal (uln) and creatinine below 2-fold uln
Description

total bilirubin, creatinine

Type de données

boolean

Alias
UMLS CUI [1]
C0201913
UMLS CUI [2]
C0201976
participants with karnofsky status greater than or equal to 60 percent
Description

karnofsky

Type de données

boolean

Alias
UMLS CUI [1]
C0206065
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
participants with previous treatment with bortezomib within 6 months before enrollment or previous treatment with a combination of rituximab and bortezomib
Description

Prior Therapy; bortezomib | Prior Therapy; bortezomib/rituximab

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1176309
UMLS CUI [2,1]
C1514463
UMLS CUI [2,2]
C1541445
participants with previous known allergic reaction to bortezomib, boron or mannitol
Description

previous known allergic reaction to bortezomib, boron or mannitol

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1176309
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0024730
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0006030
participants with life-expectancy of less than 3 months
Description

life-expectancy

Type de données

boolean

Alias
UMLS CUI [1]
C0023671
participants with malignant neoplasm (cancerous - new growth that is not normal; tumor) (except basalioma) within previous 5 years
Description

history of cancer, basalioma

Type de données

boolean

Alias
UMLS CUI [1]
C2735088
UMLS CUI [2]
C0007117
participants with peripheral (not central) neuropathy (a disturbance in the function of the brain or spinal cord that may affect the nerves and muscles of the body) common terminology criteria for adverse events (ctcae) grade greater than or equal to 2
Description

peripheral neuropathy, common terminology criteria for adverse events (ctcae)

Type de données

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C3888020
Retour au début de la page

Similar models

Eligibility Lymphoma, Follicular NCT01902862

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Lymphoma, Follicular; histological diagnosis; Recurrent disease; Refractory Disease | Lymphoma stage | Cell positive for CD20 antigen
Item
participants with histologically confirmed relapsed or refractory follicular stage iii or iv, grade 1 and 2, cluster of differentiation 20 plus (cd20+) lymphoma (who-world health organization) that requires therapy
boolean
C0024301 (UMLS CUI [1,1])
C0679557 (UMLS CUI [1,2])
C0277556 (UMLS CUI [1,3])
C1514815 (UMLS CUI [1,4])
C1272836 (UMLS CUI [2])
C0882818 (UMLS CUI [3])
rituximab planned, prior chemotherapy
Item
participants in whom treatment with rituximab is planned after greater than or equal to 2 cytostatic (inhibition of cell growth) previous therapies
boolean
C0393022 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
C1514457 (UMLS CUI [2])
postmenopausal state, sterilized, pregnancy
Item
women must be either postmenopausal or sterilized; negative pregnancy test at screening
boolean
C0232970 (UMLS CUI [1])
C0015787 (UMLS CUI [2])
C0032961 (UMLS CUI [3])
total bilirubin, creatinine
Item
participants with total bilirubin below 1.5-fold upper limit of normal (uln) and creatinine below 2-fold uln
boolean
C0201913 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
karnofsky
Item
participants with karnofsky status greater than or equal to 60 percent
boolean
C0206065 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Prior Therapy; bortezomib | Prior Therapy; bortezomib/rituximab
Item
participants with previous treatment with bortezomib within 6 months before enrollment or previous treatment with a combination of rituximab and bortezomib
boolean
C1514463 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C1514463 (UMLS CUI [2,1])
C1541445 (UMLS CUI [2,2])
previous known allergic reaction to bortezomib, boron or mannitol
Item
participants with previous known allergic reaction to bortezomib, boron or mannitol
boolean
C0020517 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0024730 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0006030 (UMLS CUI [3,2])
life-expectancy
Item
participants with life-expectancy of less than 3 months
boolean
C0023671 (UMLS CUI [1])
history of cancer, basalioma
Item
participants with malignant neoplasm (cancerous - new growth that is not normal; tumor) (except basalioma) within previous 5 years
boolean
C2735088 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
peripheral neuropathy, common terminology criteria for adverse events (ctcae)
Item
participants with peripheral (not central) neuropathy (a disturbance in the function of the brain or spinal cord that may affect the nerves and muscles of the body) common terminology criteria for adverse events (ctcae) grade greater than or equal to 2
boolean
C0031117 (UMLS CUI [1,1])
C3888020 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial